Trial site
Icon Cancer Centre Hobart
- 16running trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Conditions
- Lung cancer3 trials
- Melanoma3 trials
- Metastatic breast cancer3 trials
- Pancreatic cancer3 trials
- Prostate cancer3 trials
- Colorectal cancer2 trials
- Ovarian cancer2 trials
- Bladder cancer1 trial
- Cervical cancer1 trial
- Childhood cancers1 trial
- Endometrial cancer1 trial
- Gastric and oesophageal cancer1 trial
- and 3 more
- Phase
- Phase 39 trials
- Phase 26 trials
- Phase 2/31 trial
- Status
- Active, not recruiting8 trials
- Recruiting8 trials
- Lead sponsor
- Pfizer4 trials
- Daiichi Sankyo2 trials
- Gilead Sciences2 trials
- Regeneron Pharmaceuticals2 trials
- Verastem, Inc.2 trials
- and 4 more
Running trials
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Active, not recruiting
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer3 recruiting
- Pancreatic cancer3 recruiting
- Colorectal cancer2 recruiting
- Ovarian cancer2 recruiting
- Bladder cancer1 recruiting
- Cervical cancer1 recruiting
- Endometrial cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Head and neck cancer1 recruiting
- Melanoma1 recruiting
- Prostate cancer1 recruiting
Site data: ClinicalTrials.govUpdated 18 Nov 2026